



Clinical Program GWG Recommendations

Shyam Patel

Senior Science Officer, Portfolio Development and Review
California Institute for Regenerative Medicine


TRANSFORMING

*medicine
lives
futures*


May 24, 2018



Clinical Stage Programs



CLIN 1



CLIN 2



CLIN 3

Scoring System for Clinical Applications

- **Score of “1”**

Exceptional merit and warrants funding.

- **Score of “2”**

Needs improvement and does not warrant funding at this time but could be resubmitted to address areas for improvement.

- **Score of “3”**

*Sufficiently flawed that it does not warrant funding and the same project should not be resubmitted **for at least 6 months.***

Applications are scored by all scientific members of the GWG with no conflict.

CLIN2-10784: Phase 1 Clinical Trial of Therapy for Non-Small Cell Lung Cancer

Project Summary

Therapy	CCL21-gene modified dendritic cells combined with pembrolizumab antibody
Indication	Patients with advanced non-small cell lung cancer
Goal	Complete a phase 1 clinical trial to assess safety, maximum tolerated dose and overall response rate of therapy
Funds Requested	\$11,993,073 (\$400,000 Co-funding)

Maximum funds allowable for this category: \$12,000,000

CLIN2-10784: Phase 1 Clinical Trial of Therapy for Non-Small Cell Lung Cancer

GWG Recommendation: Exceptional merit and warrants funding

Score	GWG Votes
1	15
2	0
3	0

CIRM Team Recommendation: Fund (concur with GWG recommendation)

Award Amount: \$11,993,073*

*Final award shall not exceed this amount and may be reduced contingent on CIRM's final assessment of allowable costs and activities.